
Astragaloside IV
CAS No. 84687-43-4
Astragaloside IV( AS-IV | AST-IV )
Catalog No. M16147 CAS No. 84687-43-4
Astragaloside IV is generally considered to be the primary active ingredient in Astragalus extract,an herbal extract which has been famous for literally thousands of years for its anti-aging properties.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 29 | In Stock |
![]() ![]() |
10MG | 47 | In Stock |
![]() ![]() |
25MG | 69 | In Stock |
![]() ![]() |
50MG | 115 | In Stock |
![]() ![]() |
100MG | 192 | In Stock |
![]() ![]() |
500MG | 482 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameAstragaloside IV
-
NoteResearch use only, not for human use.
-
Brief DescriptionAstragaloside IV is generally considered to be the primary active ingredient in Astragalus extract,an herbal extract which has been famous for literally thousands of years for its anti-aging properties.
-
DescriptionAstragaloside IV is generally considered to be the primary active ingredient in Astragalus extract,an herbal extract which has been famous for literally thousands of years for its anti-aging properties.(In Vitro):Astragaloside IV (10, 20, 40 ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9. (In Vivo):Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD.
-
In VitroAstragaloside IV (10, 20, 40 ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9.
-
In VivoAstragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD.
-
SynonymsAS-IV | AST-IV
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorERS
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number84687-43-4
-
Formula Weight784.99
-
Molecular FormulaC41H68O14
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESC[C@]12CCC34C[C@@]35CCC(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)C(C)(C)C5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)CC4[C@]1(C)C[C@@H](O)[C@@H]2[C@@]8(C)CC[C@@H](C(C)(O)C)O8
-
Chemical Name(2R,3R,4S,5S,6R)-2-(((2aR,3R,4R,5aS,7R,11aR)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)hexadecahydrocyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shao A, et al. Int J Med Sci. 2014 Aug 8;11(10):1073-81.
molnova catalog



related products
-
AC-186
AC-186 is a nonsteroidal estrogen receptor β (ERβ) agonist with different affinities for ERβ and ERα, with an EC50 of 6 nM for ERβ and 5000 nM for ERα. AC-186 has neuroprotective activity and has been used in the study of Parkinson's disease.
-
Endoxifen (E-isomer)
Endoxifen E-isomer is the E-isomer of (Z)-Endoxifen. Endoxifen E-isomer has antiestrogenic effects.
-
Bazedoxifene acetate
Bazedoxifene acetate (TSE 424; WAY-TES 424), a novel selective estrogen receptor modulator (SERM).